Anika Therapeutics Q3 revenue rises on commercial channel growth
ANIK•ANIK•ANIK•ANIK•Anika Therapeutics' third-quarter revenue rose 10% year over year to $30.59 million, while adjusted net income was $3.9 million. It raised the lower end of its 2026 revenue growth and adjusted EBITDA margin outlook and expects 2027 revenue growth of flat to 5%.
Third-quarter revenue increased 10% year over year to $30.59 million, above the $29.44 million consensus estimate, as commercial channel revenue grew 17%. The company reported a net loss of $311,000 and adjusted net income of $3.9 million, reversing an adjusted loss in the year-earlier period.
Integrity revenue grew more than 30%, supported by larger implant sizes expanding use into foot and ankle and knee applications. OEM channel revenue rose 5%, supported by Hyvisc growth and J&J DePuy Synthes sales. Anika also secured a new 10-year Hyvisc partnership.
Anika raised its 2026 revenue growth guidance range to 6%-10% from 5%-10% and its adjusted EBITDA margin outlook to 15%-17% from 13%-17%. It expects total revenue growth of flat to 5% in 2027.
